NASD · Healthcare · Biotechnology · USA
Cg Oncology Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
CG Oncology is a clinical-stage biopharmaceutical company developing cretostimogene, an investigational oncolytic immunotherapy for non-muscle invasive bladder cancer. The company is evaluating the therapy through multiple clinical trials in patients with high-risk and intermediate-risk disease, including those unresponsive to BCG treatment, and has submitted a regulatory application for its initial indication.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Cg Oncology Inc stock.
Overvalued: intrinsic value $8.07 per share, market price $78.94, margin of safety -878.6% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $8.07; the price of $78.94 is 879% above that value.
17 more funds hold it; the full list is part of the paid plan.
105 more in this industry show a wider margin of safety.
CGON is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $8.07; the price of $78.94 is 879% above that value.
$8.07 per share (as of the 2026-11-17 close), against a market price of $78.94. That is a margin of safety of -878.6%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.